Plasma levels of the soluble form of the FcγRIIa receptor vary with receptor polymorphisms and are elevated in rheumatoid arthritis

References

• Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov 2012;11:311–331. doi:10.1038/nrd2909
   PubMed Web of Science ®Google Scholar
• Qiao J, Al-Tamimi M, Baker RI, Andrews RK, Gardiner EE. The platelet Fc receptor, FcγRIIa. Immunol Rev 2015;268:241–252. doi:10.1111/imr.12370
   PubMed Web of Science ®Google Scholar
• Parren PW, Warmerdam PA, Boeije LC, Arts J, Westerdaal NA, Vlug A, Capel PJ, Aarden LA, van de Winkel JG. On the interaction of IgG subclasses with the low affinity FcγRIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest 1992;90:1537–1546. doi:10.1172/JCI116022
   PubMed Web of Science ®Google Scholar
• Salmon JE, Edberg JC, Brogle NL, Kimberly RP. Allelic polymorphisms of human Fcγ receptor IIA and Fcγ receptor IIIB. Independent mechanisms for differences in human phagocyte function. J Clin Invest 1992;89:1274–1281. doi:10.1172/JCI115712
   PubMed Web of Science ®Google Scholar
• Tate BJ, Witort E, McKenzie IF, Hogarth PM. Expression of the high responder/non-responder human FcγRII. Analysis by PCR and transfection into FcR-COS cells. Immunol Cell Biol 1992;70(Pt 2):79–87. doi:10.1038/icb.1992.12
   PubMedGoogle Scholar
• Ali MM, Elghazali G, Montgomery SM, Farouk SE, Nasr A, Noori SI, Shamad MM, Fadlelseed OE, Berzins K. FcγRIIa (CD32) polymorphism and onchocercal skin disease: implications for the development of severe reactive onchodermatitis (ROD). Am J Trop Med Hyg 2007;77:1074–1078.
   PubMed Web of Science ®Google Scholar
• Forthal DN, Landucci G, Bream J, Jacobson LP, Phan TB, Montoya B. FcγRIIa genotype predicts progression of HIV infection. J Immunol 2007;179:7916–7923. doi:10.4049/jimmunol.179.11.7916
   PubMed Web of Science ®Google Scholar
• Carlsson LE, Santoso S, Baurichter G, Kroll H, Papenberg S, Eichler P, Westerdaal NAC, Kiefel V, van de Winkel JGJ, Greinacher A. Heparin-induced thrombocytopenia: new insights into the impact of the FcγRIIa-R-H131 polymorphism. Blood 1998;92:1526–1531.
   PubMed Web of Science ®Google Scholar
• Rollin J, Pouplard C, Cheng Sung H, Leroux D, Saada A, Gouilleux-Gruart V, Thibault G, Gruel Y. Increased risk of thrombosis in FcγRIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2. Blood 2015;125:2397–2404. doi:10.1182/blood-2014-09-594515
   PubMed Web of Science ®Google Scholar
• Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fcγ receptor II is critical for human IgG2 binding. J Immunol 1991;147:1338–1343.
   PubMed Web of Science ®Google Scholar
• Flinsenberg TWH, Janssen WJ, Herczenik E, Boross P, Nederend M, Jongeneel LH, Scholman RC, Boelens -J-J, Maas C, van Gijn ME, et al. A novel FcγRIIa Q27W gene variant is associated with common variable immune deficiency through defective FcγRIIa downstream signaling. Clin Immunol 2014;155:108–117. doi:10.1016/j.clim.2014.09.006
   PubMed Web of Science ®Google Scholar
• Gardiner EE, Karunakaran D, Arthur JF, Mu FT, Powell MS, Baker RI, Hogarth PM, Kahn ML, Andrews RK, Berndt MC. Dual ITAM-mediated proteolytic pathways for irreversible inactivation of platelet receptors: de-ITAM-izing FcγRIIa. Blood 2008;111:165–174. doi:10.1182/blood-2007-04-086983
   PubMed Web of Science ®Google Scholar
• Qiao J, Schoenwaelder SM, Mason KD, Tran H, Davis AK, Kaplan ZS, Jackson SP, Kile BT, Andrews RK, Roberts AW, et al. Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases prior to receiving Navitoclax (ABT-263). Blood 2013;121:1479–1481. doi:10.1182/blood-2012-12-467415
   PubMed Web of Science ®Google Scholar
• Gardiner EE, Al-Tamimi M, Mu FT, Karunakaran D, Thom JY, Moroi M, Andrews RK, Berndt MC, Baker RI. Compromised ITAM-based platelet receptor function in a patient with immune thrombocytopenic purpura. J Thromb Haemost 2008;6:1175–1182. doi:10.1111/j.1538-7836.2008.03016.x
   PubMed Web of Science ®Google Scholar
• Stack JR, Madigan A, Helbert L, Dunne E, Gardiner EE, Andrews RK, Finan R, Smyth E, Kenny D, McCarthy GM. Soluble glycoprotein VI, a specific marker of platelet activation is increased in the plasma of subjects with seropositive rheumatoid arthritis. PLoS One 2017;12:e0188027. doi:10.1371/journal.pone.0188027
   PubMed Web of Science ®Google Scholar
• Gardiner EE, Arthur JF, Kahn ML, Berndt MC, Andrews RK. Regulation of platelet membrane levels of glycoprotein VI by a platelet-derived metalloproteinase. Blood 2004;104:3611–3617. doi:10.1182/blood-2004-04-1549
   PubMed Web of Science ®Google Scholar
• Rabie T, Strehl A, Ludwig A, Nieswandt B. Evidence for a role of ADAM17 (TACE) in the regulation of platelet glycoprotein V. J Biol Chem 2005;280:14462–14468. doi:10.1074/jbc.M500041200
   PubMed Web of Science ®Google Scholar
• Kahn J, Walcheck B, Migaki GI, Jutila MA, Kishimoto TK. Calmodulin regulates L-selectin adhesion molecule expression and function through a protease-dependent mechanism. Cell 1998;92:809–818. doi:10.1016/s0092-8674(00)81408-7
   PubMed Web of Science ®Google Scholar
• Cassel DL, Keller MA, Surrey S, Schwartz E, Schreiber AD, Rappaport EF, McKenzie SE. Differential expression of FcγRIIA, FcγRIIB and FcγRIIC in hematopoietic cells: analysis of transcripts. Mol Immunol 1993;30:451–460.
   PubMed Web of Science ®Google Scholar
• Anania JC, Trist HM, Palmer CS, Tan PS, Kouskousis BP, Chenoweth AM, Kent SJ, Mackay GA, Hoi A, Koelmeyer R, et al. The rare anaphylaxis-associated FcγRIIa3 exhibits distinct characteristics from the canonical FcγRIIa1. Front Immunol 2018;9:1809. doi:10.3389/fimmu.2018.01809
   PubMed Web of Science ®Google Scholar
• Astier A, Merle-Beral H, de la Salle H, Moncuit J, Cazenave JP, Fridman WH, Hanau D, Teillaud JL. Soluble Fcγ receptor, FcγRIIa2, is present in two forms in human serum and is increased in patients: with stage C chronic lymphocytic leukemia. Leuk Lymphoma 1997;26:317–326. doi:10.3109/10428199709051781
   PubMed Web of Science ®Google Scholar
• Gachet C, Astier A, de la Salle H, de la Salle C, Fridman WH, Cazenave JP, Hanau D, Teillaud JL. Release of FcγRIIa2 by activated platelets and inhibition of anti-CD9-mediated platelet aggregation by recombinant FcγRIIa2. Blood 1995;85:698–704.
   PubMed Web of Science ®Google Scholar
• Lood C, Arve S, Ledbetter J, Elkon KB. TLR7/8 activation in neutrophils impairs immune complex phagocytosis through shedding of FcγRIIA. J Exp Med 2017;214:2103–2119. doi:10.1084/jem.20161512
   PubMed Web of Science ®Google Scholar
• Ludwig A, Hundhausen C, Lambert MH, Broadway N, Andrews RC, Bickett DM, Leesnitzer MA, Becherer JD. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. Comb Chem High Throughput Screen 2005;8:161–171.
   PubMed Web of Science ®Google Scholar
• Ierino FL, Hulett MD, McKenzie IF, Hogarth PM. Mapping epitopes of human Fcγ RII (CDw32) with monoclonal antibodies and recombinant receptors. J Immunol 1993;150:1794–1803.
   PubMedGoogle Scholar
• Roberts JJ, Rodgers SE, Drury J, Ashman LK, Lloyd JV. Platelet activation induced by a murine monoclonal antibody directed against a novel tetra-span antigen. Br J Haematol 1995;89:853–860. doi:10.1111/j.1365-2141.1995.tb08424.x
   PubMed Web of Science ®Google Scholar
• Ashman LK, Aylett GW, Mehrabani PA, Bendall LJ, Niutta S, Cambareri AC, Cole SR, Berndt MC. The murine monoclonal antibody, 14A2.H1, identifies a novel platelet surface antigen. Br J Haematol 1991;79:263–270. doi:10.1111/j.1365-2141.1991.tb04531.x
   PubMed Web of Science ®Google Scholar
• Looney RJ, Ryan DH, Takahashi K, Fleit HB, Cohen HJ, Abraham GN, Anderson CL. Identification of a second class of IgG Fc receptors on human neutrophils. A 40 kilodalton molecule also found on eosinophils. J Exp Med 1986;163:826–836. doi:10.1084/jem.163.4.826
   PubMed Web of Science ®Google Scholar
• Al-Tamimi M, Mu FT, Moroi M, Gardiner EE, Berndt MC, Andrews RK. Measuring soluble platelet glycoprotein VI in human plasma by ELISA. Platelets 2009;20:143–149. doi:10.1080/09537100802710286
   PubMed Web of Science ®Google Scholar
• Qiao J, Arthur JF, Collecutt M, Shen Y, Mu FT, Berndt MC, Davis AK, Andrews RK, Gardiner EE. An acquired defect associated with abnormal signaling of the platelet collagen receptor glycoprotein VI. Acta Haematol 2012;128:233–241. doi:10.1159/000340048
   PubMed Web of Science ®Google Scholar
• Winters R, Winters A, Amedee RG. Statistics: a brief overview. Ochsner J 2010;10:213–216.
   PubMedGoogle Scholar
• The Genomes Project, C. Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda, Maryland: National Center for Biotechnology Information, National Library of Medicine.; 2017.
   Google Scholar
• Astier A, de la Salle H, de la Salle C, Bieber T, Esposito-Farese ME, Freund M, Cazenave JP, Fridman WH, Teillaud JL, Hanau D. Human epidermal Langerhans cells secrete a soluble receptor for IgG (FcγRII/CD32) that inhibits the binding of immune complexes to FcγR+ cells. J Immunol 1994;152:201–212.
   PubMed Web of Science ®Google Scholar
• Nagarajan S, Venkiteswaran K, Anderson M, Sayed U, Zhu C, Selvaraj P. Cell-specific, activation-dependent regulation of neutrophil CD32A ligand-binding function. Blood 2000;95:1069–1077.
   PubMed Web of Science ®Google Scholar
• Mazurov AV, Vinogradov DV, Vlasik TN, Burns GF, Berndt MC. Heterogeneity of platelet Fc-receptor-dependent response to activating monoclonal antibodies. Platelets 1992;3:181–188. doi:10.3109/09537109209013181
   PubMedGoogle Scholar
• Rollin J, Pouplard C, Gratacap MP, Leroux D, May MA, Aupart M, Gouilleux-Gruart V, Payrastre B, Gruel Y. Polymorphisms of protein tyrosine phosphatase CD148 influence FcγRIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia. Blood 2012;120:1309–1316. doi:10.1182/blood-2012-04-424044
   PubMed Web of Science ®Google Scholar
• Takai T. Fc receptors and their role in immune regulation and autoimmunity. J Clin Immunol 2005;25:1–18. doi:10.1007/s10875-005-0353-8
   PubMed Web of Science ®Google Scholar
• Pritchard NR, Cutler AJ, Uribe S, Chadban SJ, Morley BJ, Smith KG. Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcγRII. Curr Biol 2000;10:227–230.
   PubMed Web of Science ®Google Scholar
• Mullazehi M, Mathsson L, Lampa J, Ronnelid J. Surface-bound anti-type II collagen-containing immune complexes induce production of tumor necrosis factor-α, interleukin-1β, and interleukin-8 from peripheral blood monocytes via Fcγ receptor IIA: a potential pathophysiologic mechanism for humoral anti-type II collagen immunity in arthritis. Arthritis Rheum 2006;54:1759–1771. doi:10.1002/art.21892
   PubMedGoogle Scholar
• de la Salle C, Esposito-Farese ME, Bieber T, Moncuit J, Morales M, Wollenberg A, de la Salle H, Fridman WH, Cazenave JP, Teillaud JL, et al. Release of soluble FcγRII/CD32 molecules by human Langerhans cells: a subtle balance between shedding and secretion? J Invest Dermatol 1992;99:15S–17S.
   PubMed Web of Science ®Google Scholar
• Semenov AV, Romanov YA, Loktionova SA, Tikhomirov OY, Khachikian MV, Vasil’ev SA, Mazurov AV. Production of soluble P-selectin by platelets and endothelial cells. Biochemistry 1999;64:1326–1335.
   PubMed Web of Science ®Google Scholar
• Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, Weinblatt ME, Massarotti EM, Remold-O’Donnell E, Farndale RW, Ware J, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 2010;327:580–583. doi:10.1126/science.1181928
   PubMed Web of Science ®Google Scholar
• Lee YH, Bae SC, Song GG. FCGR2A, FCGR3A, FCGR3B polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis. Clin Exp Rheumatol 2015;33:647–654.
   PubMed Web of Science ®Google Scholar
• Kyogoku C, Tsuchiya N, Matsuta K, Tokunaga K. Studies on the association of Fcγ receptor IIA, IIB, IIIA and IIIB polymorphisms with rheumatoid arthritis in the Japanese: evidence for a genetic interaction between HLA-DRB1 and FCGR3A. Genes Immun 2002;3:488–493. doi:10.1038/sj.gene.6363921
   PubMed Web of Science ®Google Scholar